318 related articles for article (PubMed ID: 29484893)
1. Generalized Pustular Psoriasis Induced by Infliximab in a Patient With Inflammatory Bowel Disease.
Almutairi D; Sheasgreen C; Weizman A; Alavi A
J Cutan Med Surg; 2018; 22(5):507-510. PubMed ID: 29484893
[TBL] [Abstract][Full Text] [Related]
2. Stricturing and Fistulizing Crohn's Disease Is Associated with Anti-tumor Necrosis Factor-Induced Psoriasis in Patients with Inflammatory Bowel Disease.
Weizman AV; Sharma R; Afzal NM; Xu W; Walsh S; Stempak JM; Nguyen GC; Croitoru K; Steinhart AH; Silverberg MS
Dig Dis Sci; 2018 Sep; 63(9):2430-2438. PubMed ID: 29736839
[TBL] [Abstract][Full Text] [Related]
3. Psoriasiform and pustular eruption induced by infliximab.
Takahashi H; Hashimoto Y; Ishida-Yamamoto A; Ashida T; Kohgo Y; Iizuka H
J Dermatol; 2007 Jul; 34(7):468-72. PubMed ID: 17584325
[TBL] [Abstract][Full Text] [Related]
4. Paradoxical psoriasiform reactions of anti-tumour necrosis factor therapy in inflammatory bowel disease patients.
Peer FC; Miller A; Pavli P; Subramaniam K
Intern Med J; 2017 Dec; 47(12):1445-1448. PubMed ID: 29224199
[TBL] [Abstract][Full Text] [Related]
5. Case of psoriasiform and pustular eruptions in addition to alopecia as a paradoxical reaction induced by infliximab.
Shimokata M; Namiki T; Tokoro S; Ugajin T; Miura K; Yokozeki H
J Dermatol; 2018 Dec; 45(12):e331-e333. PubMed ID: 29855072
[No Abstract] [Full Text] [Related]
6. Psoriasis and Psoriasiform Eruptions in Pediatric Patients with Inflammatory Bowel Disease Treated with Anti-Tumor Necrosis Factor Alpha Agents.
Eickstaedt JB; Killpack L; Tung J; Davis D; Hand JL; Tollefson MM
Pediatr Dermatol; 2017 May; 34(3):253-260. PubMed ID: 28211161
[TBL] [Abstract][Full Text] [Related]
7. Clinical management of Anti-TNF-alpha-induced psoriasis or psoriasiform lesions in inflammatory bowel disease patients: a systematic review.
Melo FJ; Magina S
Int J Dermatol; 2018 Dec; 57(12):1521-1532. PubMed ID: 30028008
[TBL] [Abstract][Full Text] [Related]
8. Induction of psoriasis with anti-TNF agents in patients with inflammatory bowel disease: a report of 21 cases.
Guerra I; Algaba A; Pérez-Calle JL; Chaparro M; Marín-Jiménez I; García-Castellanos R; González-Lama Y; López-Sanromán A; Manceñido N; Martínez-Montiel P; Quintanilla E; Taxonera C; Villafruela M; Romero-Maté A; López-Serrano P; Gisbert JP; Bermejo F
J Crohns Colitis; 2012 Jun; 6(5):518-23. PubMed ID: 22398059
[TBL] [Abstract][Full Text] [Related]
9. The association of psoriasiform rash with anti-tumor necrosis factor (anti-TNF) therapy in inflammatory bowel disease: a single academic center case series.
Afzali A; Wheat CL; Hu JK; Olerud JE; Lee SD
J Crohns Colitis; 2014 Jun; 8(6):480-8. PubMed ID: 24268978
[TBL] [Abstract][Full Text] [Related]
10. Cutaneous adverse reaction to infliximab: report of psoriasis developing in 3 patients.
Severs GA; Lawlor TH; Purcell SM; Adler DJ; Thompson R
Cutis; 2007 Sep; 80(3):231-7. PubMed ID: 17956013
[TBL] [Abstract][Full Text] [Related]
11. Incidence of psoriasiform diseases secondary to tumour necrosis factor antagonists in patients with inflammatory bowel disease: a nationwide population-based cohort study.
Bae JM; Lee HH; Lee BI; Lee KM; Eun SH; Cho ML; Kim JS; Park JM; Cho YS; Lee IS; Kim SW; Choi H; Choi MG
Aliment Pharmacol Ther; 2018 Jul; 48(2):196-205. PubMed ID: 29869804
[TBL] [Abstract][Full Text] [Related]
12. Association Between Infliximab Trough Levels and the Occurrence of Paradoxical Manifestations in Patients with Inflammatory Bowel Disease: a Case-Control Study.
Coutzac C; Chapuis J; Poullenot F; Chabrun E; Capdepont M; Blanco P; Laharie D
J Crohns Colitis; 2015 Nov; 9(11):982-7. PubMed ID: 26351388
[TBL] [Abstract][Full Text] [Related]
13. Paradoxical Psoriasiform Eruptions in Children Receiving Tumor Necrosis Factor α Inhibitors.
Eickstaedt J; Paller AS; Lund E; Murphrey M; Brandling-Bennett H; Maurano M; Fernandez Faith E; Holland KE; Ibler E; Liang MG; Todd PS; Siegfried E; Igelman S; Cordoro KM; Tollefson MM
JAMA Dermatol; 2023 Jun; 159(6):637-642. PubMed ID: 37043214
[TBL] [Abstract][Full Text] [Related]
14. Anti-TNFα antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease: an Irish Cohort Study.
Kirthi Jeyarajah S; Tobin AM; Hussey M; Scaldaferri F; McNamara D
QJM; 2017 Jun; 110(6):379-382. PubMed ID: 28069913
[TBL] [Abstract][Full Text] [Related]
15. Psoriasis associated with anti-tumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literature.
Cullen G; Kroshinsky D; Cheifetz AS; Korzenik JR
Aliment Pharmacol Ther; 2011 Dec; 34(11-12):1318-27. PubMed ID: 21957906
[TBL] [Abstract][Full Text] [Related]
16. Infliximab-induced skin manifestations in patients with inflammatory bowel disease.
Hellström AE; Färkkilä M; Kolho KL
Scand J Gastroenterol; 2016; 51(5):563-71. PubMed ID: 26728295
[TBL] [Abstract][Full Text] [Related]
17. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis.
Collamer AN; Battafarano DF
Semin Arthritis Rheum; 2010 Dec; 40(3):233-40. PubMed ID: 20580412
[TBL] [Abstract][Full Text] [Related]
18. Psoriasiform Skin Lesions Are Caused by Anti-TNF Agents Used for the Treatment of Inflammatory Bowel Disease.
George LA; Gadani A; Cross RK; Jambaulikar G; Ghazi LJ
Dig Dis Sci; 2015 Nov; 60(11):3424-30. PubMed ID: 26115749
[TBL] [Abstract][Full Text] [Related]
19. Induction or exacerbation of psoriatic lesions during anti-TNF-α therapy for inflammatory bowel disease: a systematic literature review based on 222 cases.
Denadai R; Teixeira FV; Steinwurz F; Romiti R; Saad-Hossne R
J Crohns Colitis; 2013 Aug; 7(7):517-24. PubMed ID: 22960136
[TBL] [Abstract][Full Text] [Related]
20. Six Cases of Lung Injury Following Anti-tumour Necrosis Factor Therapy for Inflammatory Bowel Disease.
Lee HS; Jo KW; Shim TS; Song JW; Lee HJ; Hwang SW; Park SH; Yang DH; Kim KJ; Ye BD; Byeon JS; Myung SJ; Kim JH; Yang SK
J Crohns Colitis; 2015 Nov; 9(11):1053-7. PubMed ID: 26221002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
